M
Martin S. Tallman
Researcher at Memorial Sloan Kettering Cancer Center
Publications - 948
Citations - 71451
Martin S. Tallman is an academic researcher from Memorial Sloan Kettering Cancer Center. The author has contributed to research in topics: Myeloid leukemia & Leukemia. The author has an hindex of 117, co-authored 917 publications receiving 60011 citations. Previous affiliations of Martin S. Tallman include University of Rome Tor Vergata & University of Toronto.
Papers
More filters
Journal ArticleDOI
Effect of additional cytogenetic abnormalities on survival in arsenic trioxide-treated acute promyelocytic leukemia
Zachary D. Epstein-Peterson,Andriy Derkach,Susan Geyer,Krzysztof Mrózek,Jessica Kohlschmidt,Jae H. Park,Sridevi Rajeeve,Eytan M. Stein,Yanming Zhang,Harry J. Iland,J. Campbell,Richard A. Larson,Xavier Poiré,Bayard L. Powell,Wendy Stock,Richard Stone,Martin S. Tallman +16 more
TL;DR: Key Point Complex karyotype is associated with inferior event-free survival in patients who have acute promyelocytic leukemia treated with ATO.
Journal ArticleDOI
Ratify (Alliance 10603): Prognostic Impact of FLT3 tyrosine Kinase Domain (TKD) and NPM1 Mutation Status in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) Treated with Midostaurin or Placebo Plus Standard Chemotherapy
Maria Teresa Voso,Richard A. Larson,Thomas W. Prior,Guido Marcucci,Dan Jones,Jürgen Krauter,Michael Heuser,Serena Lavorgna,J. Nomdedeu,Susan Geyer,Rebecca B. Klisovic,Andrew H. Wei,Jorge Sierra,Miguel A. Sanz,Joseph Brandwein,Theo de Witte,Joop H. Jansen,Dietger Niederweiser,Frederick R. Appelbaum,Bruno C. Medeiros,Martin S. Tallman,Richard F. Schlenk,Arnold Ganser,Sergio Amadori,Yuan Cheng,Insa Gathmann,Eva Tiecke,Christian Thiede,Konstanze Döhner,Hartmut Döhner,Richard Stone,Clara D. Bloomfield,Francesco Lo-Coco +32 more
TL;DR: The prognostic effect of the NPM1 mutation concurrent with FLT3-TKD was seen for all endpoints consistently with hazard ratios (HRs) around 0.50 or lower (Figures 1 and 2 and Table).
Journal ArticleDOI
Integrative Genome-Wide DNA Methylation and Gene Expression Analysis Reveals Biological and Clinical Insights In Adult Acute Lymphoblastic Leukemia
Huimin Geng,Donna Neuberg,Elisabeth Paietta,Xutao Deng,Yushan Li,Yuan Xin,Janis Racevskis,Rhett P. Ketterling,Susan M. Richards,Martin S. Tallman,Jacob M. Rowe,Mark R. Litzow,Olivier Elemento,Ari Melnick +13 more
TL;DR: In this paper, the authors performed genome-wide DNA methylation and gene expression microarray studies of 215 adult patients with B-lineage ALL enrolled in the ECOG E2993 phase III trial.
Journal ArticleDOI
Phase II trial of WT1 analog peptide vaccine in adults with acute myeloid leukemia (AML) in first complete remission (CR).
Peter Maslak,Tao Dao,Yvette Bernal,Suzanne Chanel,Rong Zhang,Mark G. Frattini,Todd L. Rosenblat,Joseph G. Jurcic,Raajit K. Rampal,Jae Hong Park,Dan Douer,Laura Katz,Andres A. Gutierrez,Martin S. Tallman,David A. Scheinberg +14 more
TL;DR: This work reports on the safety, immunogenicity, and prolonged tolerability of WT1 in patients with atypical central giant cell types.
Journal ArticleDOI
Combined Treatment with Lenalidomide and Epoetin Alfa Leads to Durable Responses in Patients with Epo-Refractory, Lower Risk Non-Deletion 5q [Del(5q)] MDS: Final Results of the E2905 Intergroup Phase III Study - an ECOG-ACRIN Cancer Research Group Study, Grant CA180820, and the National Cancer Institute of the National Institutes of Health
Alan F. List,Zhuoxin Sun,Amit Verma,John M. Bennett,Kathy L. McGraw,Jaroslaw P. Maciejewski,Rami S. Komrokji,Timothy R. Wassenaar,Selina M. Luger,Ryan J. Mattison,Puneet Cheema,Jessica K. Altman,David F. Claxton,Charles A. Schiffer,Andrew S. Artz,Mark R. Litzow,Martin S. Tallman +16 more
TL;DR: Komrokji et al. as mentioned in this paper reported that the addition of epoetin alfa (EA) to LEN treatment yielded a significant improvement in patients' response to rhEpo.